Evidence map›Paper›PMID 40359030›Full record

ArticleJCI insight2025

Chemotherapy and the somatic mutation burden of sperm.

Shany Picciotto, Camilo Arenas-Gallo, Amos Toren, Ruty Mehrian-Shai, Bryan Daly, Stephen Rhodes, Megan Prunty, Ruolin Liu, Anyull Bohorquez, Marta Grońska-Pęski and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Effects of Cytotoxic Therapies on the Sperm Genome and Epigenome.Advances in experimental medicine and biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Shany PicciottoDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Camilo Arenas-GalloDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Amos TorenPediatric Hemato-Oncology, Sheba Medical Center, Ramat Gan, Israel.
Ruty Mehrian-ShaiPediatric Hemato-Oncology, Sheba Medical Center, Ramat Gan, Israel.
Bryan DalyDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Stephen RhodesDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Megan PruntyDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Ruolin LiuBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Anyull BohorquezDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Marta Grońska-PęskiCenter for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, New York, USA.
Shana MelanaphyCalifornia Cryobank, Los Angeles, California, USA.
Pamela CallumTandem Genetics, Los Angeles, California, USA.
Emilie LassenCryos International, Aarhus, Denmark.
Anne-Bine SkytteCryos International, Aarhus, Denmark.
Rebecca C ObengCase Comprehensive Cancer Center and.
Christopher BarbieriDepartment of Urology, Weill Cornell Medical College, New York, New York, USA.
Molly GalloglyDivision of Hematology and Cell Therapy and.
Brenda CooperCase Comprehensive Cancer Center and.
Katherine DaunovDivision of Hematology and Cell Therapy and.
Lydia BeardDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Koen van BesienCase Comprehensive Cancer Center and.
Joshua HalpernDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Quintin PanCase Comprehensive Cancer Center and.
Gilad D EvronyCenter for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, New York, USA.
Viktor A AdalsteinssonBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Jonathan E ShoagDepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Funding

Direct measurement of the male germline mutation rate using sequential sperm samplesR21HD105910 · NICHD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI EVRONY, GILAD DAVID, SHOAG, JONATHAN · 2021 to 2022
$479k
NICHD NIH HHS R21 HD105910
6 · The paper itself

Abstract

Many chemotherapeutic agents impair cancer growth by inducing DNA damage. The impact of these agents on mutagenesis in normal cells, including sperm, is largely unknown. Here, we applied high-fidelity duplex sequencing to 94 samples from 36 individuals exposed to diverse chemotherapies and 32 controls. We found that in many of the sperm samples from men exposed to chemotherapy, the mutation burden was elevated as compared with controls and the expected burden based on trio studies, with 1 patient having a more than 10-fold increase over that expected for age. Saliva from this same individual also had a markedly higher mutation burden. We then validated this finding using other tissues, also finding an increased mutation burden in the blood and liver of many patients exposed to chemotherapy as compared with unexposed controls. Similarly, mice treated with 3 cycles of cisplatin had an increased mutation burden in sperm but also in the liver and hematopoietic progenitor cells. These results suggest an association between cancer therapies and mutation burden, with implications for counseling patients with cancer considering banking sperm before therapy and for cancer survivors considering the trade-offs of using banked sperm as compared with conceiving naturally.

Indexed as

Antineoplastic AgentsMutationNeoplasmsSpermatozoaAdultAnimalsCisplatinDNA DamageHumansMaleMiceMiddle AgedAntineoplastic AgentsCisplatinCancerGenetic diseasesGeneticsOncologyReproductive biologyUrology

Identifiers

PMID40359030
PMCPMC12220962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.